Quarterly report pursuant to Section 13 or 15(d)

7. STOCKHOLDERS' EQUITY (Details 2)

v3.19.2
7. STOCKHOLDERS' EQUITY (Details 2) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Total stock-based compensation expense $ 726,736 $ 535,391 $ 1,363,999 $ 1,050,175
Research and development        
Total stock-based compensation expense 89,543 83,339 176,066 161,644
Plasma centers        
Total stock-based compensation expense 13,213 7,760 24,753 14,846
Selling, general and administrative        
Total stock-based compensation expense 569,349 406,193 1,067,820 801,050
Cost of product revenue        
Total stock-based compensation expense $ 54,631 $ 38,099 $ 95,360 $ 72,635